bearish
China Healthcare Weekly (Sep.25) - CXO Trading Strategy, Plunge in Medical Beauty, Belief in Biotech
316 Views26 Sep 2022 08:35
If investor still want to trade CXO,here are two suggestions; The plunge in medical beauty sector last week was due to industry-wide rectification; Biotech is still the core of pharmaceutical industry
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
- MicroPort NeuroTech (2172.HK) 22H1 - Advantages Deserve Recognition, but with Overvaluation Risk06 Oct 2022
- Shanghai United Imaging Healthcare (688271.CH) - Overvalued; Stock Price Will Return to Rationality04 Oct 2022
- China Healthcare Weekly (Sep.30) - Orthopedics VBP, CGT CDMO, Surgical Robots, Bottom of HKEX02 Oct 2022
- Remegen Co Ltd (9995.HK) 22H1 - Mr. Market's "Misjudgment" Brings Opportunities to Make Money21 Sep 2022
- Aier Eye Hospital (300015.CH) 22H1 - More Downside Ahead; The Long Logic Doesn't Exist20 Sep 2022
- About the CXO Plunge After Biden Signed National Biotechnology and Biomanufacturing Initiative19 Sep 2022
x